

REMARKS

Claims 1-11 are pending in the above-identified application and the Examiner has subjected the claims to a restriction requirement. The Examiner asserts that the inventions of Groups I-III are distinct and have acquired a separate status in the art because of their recognized divergent subject matter under PCT Rule 13.1. Accordingly, the Examiner requires that Applicants elect the subject matter of one of Groups I-III for prosecution in the present application. By this response, Applicants have elected the invention of Group I, and have traversed the Examiner's restriction requirement.

Applicants traverse the restriction requirement only to the extent that the restriction requirement does not allow Applicants to prosecute the subject matter of Group I and the subject matter of Group III in the same application. While Applicants recognize that the compounds within the two groups (Group I and Group III) differ with respect to the same essential structural element(s) that define the "special technical feature", Applicants submit that it does not appear to be overly burdensome to allow Applicants to prosecute the subject matter of Groups I and III in the same application since, as the Examiner has acknowledged, the compounds of Groups I and III share the same core structural moiety. Accordingly, Applicants request that they be allowed to prosecute the subject matter of Groups I and III in the present application.

Respectfully submitted,

Date: July 23, 2008

/B. Timothy Creagan/

B. Timothy Creagan
Attorney for Applicants
Reg. No. 39,156

Pfizer Inc.
Patent Dept
Eastern Point Road, MS8260-1611
Groton, CT 06340
(860) 715-4546